Elanco vs Jazz Pharmaceuticals
Add, change or remove companies; up to four.
KIRA’s take AI analyst
I put Elanco and Jazz Pharmaceuticals side by side, using each one’s latest annual report. Here is what stands out:
- Elanco is the larger business, with $4.7B of revenue in fiscal 2025 against $4.3B for Jazz Pharmaceuticals.
- Elanco grew revenue faster (6.2%, against 4.9%).
- Jazz Pharmaceuticals turned more of its sales into free cash flow (30.4% FCF margin, against 6.0%).
- Elanco earned a higher return on the capital invested in it (−0.1%, against −4.2%).
Who comes out ahead
Of the 8 measures where higher (or lower) is clearly better, how many each company leads.
Elanco
ELAN
5/8
Revenue growthNet marginReturn on capitalReturn on equityPiotroski F-score
Jazz Pharmaceuticals
JAZZ
3/8
5-year growthFCF marginShare count change
Side by side
Best in the row
| Latest fiscal year | ELAN FY25 | JAZZ FY25 |
|---|---|---|
| Size | ||
| Market cap | $11.6B | $14.3B |
| Revenue | $4.7B | $4.3B |
| Free cash flow | $284M | $1.3B |
| Net income | −$232M | −$356M |
| Growth | ||
| Revenue growth | 6.2% | 4.9% |
| 5-year growth | 7.6% | 12.5% |
| Share count change | −0.2% | −7.6% |
| Profitability | ||
| Gross margin | 55.0% | — |
| Operating margin | — | −10.1% |
| Net margin | −4.9% | −8.4% |
| FCF margin | 6.0% | 30.4% |
| Return on capital | −0.1% | −4.2% |
| Return on equity | −3.7% | −8.5% |
| Balance sheet | ||
| Net debt | $3.5B | $4.0B |
| Net debt / EBITDA | 5.2x | — |
| Dividends and buybacks | $0.0M | $125M |
| Valuation & quality | ||
| P/E | — | 14.1x |
| Piotroski F-score | 6 | 4 |
Ten years
Revenue
Operating margin
Free cash flow
Return on capital
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.